NeoGenomics reported fourth‑quarter revenue of $190.2 million, up 11% year‑over‑year and topping consensus, driven by a shift to higher‑value testing and strong clinical revenue growth. The company said next‑generation sequencing (NGS) revenues grew roughly 23% in Q4 and 22% for the full year, outpacing market averages. Management plans to add about 25 oncology salespeople by the end of the third quarter to push commercial adoption. Adjusted EPS and full‑year guidance beat expectations, though clinical testing volumes were slightly lighter than internal forecasts. NeoGenomics’ results reflect sustained demand for molecular oncology diagnostics and the strategic importance of NGS adoption in both clinical and trial settings.